Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness
Por:
Cortijo-Cascajares S, Cercós-Lletí AC, Ortiz-Pérez S, Caro-Teller JM and Ferrari-Piquero JM
Publicada:
15 dic 2021
Ahead of Print:
1 dic 2021
Resumen:
Objective: To study immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab, as well as to assess whether these reactions could be predictors of further effectiveness of therapy.
Methods: Retrospective, observational and longitudinal study. All NSCLC patients who received nivolumab between February 2015-May 2020 were included. In terms of safety, irAEs and their severity were registered and to evaluate the effectiveness, overall survival (OS) and progression free survival (PFS) were calculated.
Results: 75 patients were included. 32 patients (43%) were reported irAES. Mainly the irAEs affected the skin (36%). Followed by pneumonitis (20%), gastrointestinal reactions (12%), endocrine (12%) and hepatitis (12%). Regarding severity, 92% were moderate. The median PFS was 9.49 months on the group with irAEs versus 1.99 months on the group without irAEs group (p < 0.0001). The median OS was 17.44 months versus 7.67 months respectively (p = 0.0001). According to the incidence of irAEs developed ( = > 2 vs. 1 vs. 0), the median PFS was 20.53 versus 5.35 versus 1.99 months respectively (p < 0.0001). The median OS was 23.41 versus 15.80 versus 7.67 months, respectively (p = 0.0002)
Conclusion: In a significant number of patients irAEs occur, generally of grade 1-2 severity, affecting mainly the skin, lungs and gastrointestinal system. We confirm that the development of irAEs in patients with NSCLC treated with nivolumab is a strong predictor of treatment effectiveness in both PFS and OS, with statistically significant results. On those patients who experience two or more immunorelated adverse events the greatest benefit has been observed.
Filiaciones:
Cortijo-Cascajares S:
Department of Pharmacy, 16473Hospital Universitario 12 de Octubre, Madrid, Spain
:
Department of Pharmacy, 16804Hospital Universitario Dr Peset, Valencia, Spain
Ortiz-Pérez S:
Department of Pharmacy, 16473Hospital Universitario 12 de Octubre, Madrid, Spain
Caro-Teller JM:
Department of Pharmacy, 16473Hospital Universitario 12 de Octubre, Madrid, Spain
Ferrari-Piquero JM:
Department of Pharmacy, 16473Hospital Universitario 12 de Octubre, Madrid, Spain
|